Augustine Therapeutics Series A 2025

TLDR

Augustine Therapeutics raised EUR 77.7M in a Series A round in March 2025, led by Novo Holdings and Jeito Capital, to advance its treatments for neuromuscular and neurodegenerative diseases.

Overview

The EUR 77.7M Series A is one of the largest single Series A rounds in Belgian biotech history. Lead investor Novo Holdings, the investment arm of the Novo Nordisk Foundation, is one of the most active and credible life sciences investors globally. Co-lead Jeito Capital is a Paris-based growth biotech fund with a European focus.

Augustine Therapeutics develops small molecule treatments targeting neuromuscular and neurodegenerative conditions. The capital will support clinical advancement of its lead programs.

The round underscores Belgium's standing as a top-tier European biotech hub, with Ghent and Leuven producing successive large raises in the life sciences space.